Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

SUPN stock hub

Supernus Pharmaceuticals, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

SUPNis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

SUPN

In the news

Latest news · SUPN

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E19.6

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-2.8

P25 -105.6P50 -46.5P75 -3.1

ROIC3.3

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All SUPN market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

247

Groups with data

Currency

USD

Showing 247 of 247 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001356576
Company name	Supernus Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	868459108
Employees	778
Employees Change	104%
Employees Change Percent	15.43
Enterprise value	$2.6B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2012-05-01
Isin	US8684591089
Last refreshed	2026-05-10
Market cap	$3B
Market cap category	Mid-Cap
Price	$51.53
Price currency	USD
Rev Per Employee	998,500x
Sector	Healthcare
Sic	2834
Symbol	SUPN
Website	https://www.supernus.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-0.97%
EV Sales Forward	2.86x
EV/EBIT	104.58x
EV/EBITDA	21.59x
EV/FCF	32.19x
EV/Sales	3.41x
FCF yield	2.75%
Forward P/E	19.59x
P/B ratio	2.78x
P/S ratio	3.85x
PE Ratio10 Y	64.34x
PE Ratio3 Y	211.42x
PE Ratio5 Y	120.12x
PEG ratio	0.71x
PS Forward	3.23x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	3.26%
EBITDA Margin	15.79%
FCF margin	10.59%
Gross margin	74.13%
Gross Profit	$575.9M
Gross Profit Growth	26.59%
Gross Profit Growth Q	35.23%
Gross Profit Growth3 Y	0.01%
Gross Profit Growth5 Y	3.15%
Net Income	$-29M
Net Income Growth Quarters	1%
Net Income Growth Years	0%
Pretax Margin	-6.33%
Profit Margin	-3.74%
Profit Per Employee	$-37,296
ROA	1.11
Roa5y	1.88
ROCE	2.25
ROE	-2.75
Roe5y	3.6
ROIC	3.32
Roic5y	4.69

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	13.05%
Cagr1y	66.61%
Cagr3y	11.96%
Cagr5y	11.9%
EPS Growth Quarters	1
EPS Growth Years	0
FCF Growth	-49.65%
FCF Growth Q	119.75%
FCF Growth3 Y	-20.19%
FCF Growth5 Y	-12.74%
OCF Growth	-49.28%
OCF Growth Q	117.41%
OCF Growth10 Y	10.16%
OCF Growth3 Y	-19.84%
OCF Growth5 Y	-12.86%
Revenue Growth	16.29x
Revenue Growth Q	38.63x
Revenue Growth Quarters	3x
Revenue Growth Years	2x
Revenue Growth3 Y	5.13x
Revenue Growth5 Y	6.9x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.55
Assets	$1.5B
Cash	$384.2M
Current Assets	$731.6M
Current Liabilities	$373.9M
Debt	$40.9M
Debt EBITDA	$0.29
Debt Equity	$0.04
Debt FCF	$0.5
Equity	$1.1B
Liabilities	$423.9M
Long Term Assets	$769.1M
Long Term Liabilities	$50M
Net Cash	$343.3M
Net Cash By Market Cap	$11.48
Net Cash Growth	-20.39%
Net Debt EBITDA	$-2.8
Net Debt Equity	$-0.32
Net Debt FCF	$-4.17
Tangible Book Value	$406.4M
Tangible Book Value Per Share	$7
WACC	7.29

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.96
Inventory Turnover	2.94
Net Working Capital	$-16M
Quick ratio	1.51
Working Capital	$357.7M
Working Capital Turnover	$2.04

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1.57%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	240.81%
1Y total return	66.55%
200-day SMA	48.13
3Y total return	40.37%
50-day SMA	50.82
50-day SMA vs 200-day SMA	50over200
5Y total return	75.45%
All Time High	61.25
All Time High Change	-15.87%
All Time High Date	2018-06-29
All Time Low	4.3
All Time Low Change	1,098.37%
All Time Low Date	2012-06-05
ATR	2.08
Beta	0.57
Beta1y	0.77
Beta2y	0.52
Ch YTD	3.68
High	52.59
High52	59.68
High52 Date	2026-02-25
High52ch	-13.66%
Low	50.36
Low52	30.44
Low52 Date	2025-05-08
Low52ch	69.28%
Ma50ch	1.41%
Premarket Change Percent	0.98
Premarket Price	$52.79
Premarket Volume	1,203
Price vs 200-day SMA	7.07%
RSI	56.84
RSI Monthly	60.47
RSI Weekly	55.52
Sharpe ratio	1.51x
Sortino ratio	2.37
Total Return	-1.57%
Tr YTD	3.68
Tr1m	1.12%
Tr1w	7.69%
Tr3m	-0.23%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	5
Analyst Count Top	3
Analyst Price Target Top	$61
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$0.25
Earnings Revenue Estimate	192,024,168x
Earnings Revenue Estimate Growth	28.17x
Operating Income	$25.3M
Operating Income Growth	-56.8
Operating Income Growth3 Y	-18.35
Operating Income Growth5 Y	-31.61
Operating margin	3.26
Price target	$61.6
Price Target Change	$19.54
Price Target Change Top	$18.38

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	52,247,461%
Float Percent	90.02%
Shares Insiders	4.3%
Shares Institutions	96.46%
Shares Out	58,039,721
Shares Qo Q	0.53%
Shares Yo Y	1.57%
Short Float	9.06%
Short Ratio	8.37
Short Shares	8.15

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$48.8M
Average Volume	714,688.45x
Bv Per Share	18.55
CAPEX	$-1M
Ch10y	240.8
Ch1m	1.12
Ch1w	7.69
Ch1y	66.55
Ch3m	-0.23
Ch3y	40.37
Ch5y	75.45
Ch6m	11.97
Change	-1.43%
Change From Open	-1.77
Close	52.28
Days Gap	0.34
Depreciation Amortization	97,312,000
Dollar Volume	44,038,568.6
Earnings Date	2026-05-05
Earnings Time	amc
EBIT	$25.3M
EBITDA	$122.6M
EPS	$-0.51
F Score	5
FCF	$82.2M
FCF EV Yield	3.11x
FCF Per Share	$1.42
Financing CF	39,644,000
Fiscal Year End	December
Founded	2,005
Goodwill	120,668,000
Income Tax	$-20.1M
Investing CF	-52,429,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-05
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-02
Ma150	49.84
Ma150ch	3.38%
Ma20	49.85
Ma20ch	3.36%
Net CF	70,471,000
Next Earnings Date	2026-08-04
Open	52.46
Optionable	Yes
P FCF Ratio	36.36
P OCF Ratio	35.92
Position In Range	52.47
Post Close	51.53
Postmarket Change Percent	1.9
Postmarket Price	$52.51
Ppne	36,439,000
Pre Close	52.28
Price Date	2026-05-08
Price EBITDA	$24.39
Ptbv Ratio	7.36
Relative Volume	1.2x
Revenue	776,833,000x
SBC By Revenue	4.31x
Share Based Comp	33,463,000
Tax By Revenue	-2.59x
Tr6m	11.97%
Us State	Maryland
Volume	854,620
Z Score	4.78

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does SUPN pay a dividend?

Capital-return profile for this ticker.

Performance

SUPN stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns SUPN?

Insider, institutional, and short-interest positioning.

Institutional ownership

+96.5%

Float: +90.0% of shares outstanding

Insider ownership

+4.3%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

SUPN momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

56.8

Neutral momentum band

Price vs 200-day MA

+7.1%

50/200-day relationship not available

Beta (5Y)

0.57

Less volatile than the market

Sharpe ratio

1.51

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About SUPN

Hub-level FAQ points readers to the deeper analysis pages.

What is the current SUPN stock rating?

Supernus Pharmaceuticals, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full SUPN analysis?

The full report lives at /stocks/SUPN/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for SUPN?

The latest report frames SUPN around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the SUPN page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.